Note: The Gail Model is most accurate for women over 35 without a personal history of LCIS or DCIS. A 5-year risk ≥ 1.67% is considered "high risk" and may justify chemoprevention.
Guidelines & Evidence
Clinical Details
Section 1
When to Use
Primary Clinical Uses
Estimating the 5-year and lifetime risk of developing invasive breast cancer in women aged 35 years and older.
Determining eligibility for prophylactic breast cancer risk-reducing medications (Tamoxifen/Raloxifene).
Triaging patients for enhanced screening protocols (e.g., adjunctive Breast MRI).
Exclusion Criteria
This tool is useless and invalid for patients with known BRCA1/BRCA2 genetic mutations, patients with a history of Lobular/Ductal Carcinoma In Situ (LCIS/DCIS), or those who have received prior medical radiation to the chest.
Section 2
Formula & Logic
The Required Variables
Current Age of the patient.
Age at menarche (earlier is higher estrogen exposure risk).
Age at the time of first live birth (or nulliparity; older age is higher risk).
Number of first-degree female relatives (mother, sister, daughter) with breast cancer.
Number of previous benign breast biopsies.
Presence of Atypical Hyperplasia explicitly confirmed on a prior biopsy.
Scoring Threshold
5-Year Risk ≥ 1.67%
Considered "High Risk". Chemoprevention discussion indicated.
5-Year Risk < 1.67%
Standard screening protocols.
Section 3
Pearls/Pitfalls
Model Limitations
The Gail Model only considers FIRST-degree relatives. It entirely ignores paternal history, second-degree relatives, and the age of onset of cancer in those relatives.
Calculates the risk of INVASIVE breast cancer only, completely stripping out the risk for developing non-invasive in-situ ductal disease.
African American and Hispanic populations historically had their risks underestimated until subsequent mathematical calibrations were added; always utilize an ethnicity-adjusted version if available.
Section 4
Next Steps
Actionable Chemoprevention
01
If 5-Year risk exceeds 1.67%, initiate a shared-decision making discussion regarding SERMs (Selective Estrogen Receptor Modulators).
02
Premenopausal High Risk: Consider Tamoxifen for 5 years.
03
Postmenopausal High Risk: Consider Tamoxifen, Raloxifene, or Aromatase Inhibitors.
04
Caution: SERMs significantly increase the risk of deep vein thrombosis (DVT/PE) and endometrial cancer. Baseline absolute risk must outweigh these side-effects.
Section 5
Evidence Appraisal
The Original Validation
Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.
Gail MH et al. • J Natl Cancer Inst.. 1989;The massive Breast Cancer Detection Demonstration Project (BCDDP) dataset that established the foundational multivariable logistic regression equation.
Section 6
Literature
Dr. Mitchell Gail
Dr. Mitchell Gail introduced this algorithm to specifically help clinical trial managers identify high-risk women who were mathematically optimal for inclusion in the landmark Breast Cancer Prevention Trial (BCPT), ensuring enough statistical power could be reached.
